Contact Us

GENTAUR Europe

 GENTAUR Europe BVBA
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 
Fax 0032 16 50 90 45
This email address is being protected from spambots. You need JavaScript enabled to view it.  

Gentaur Bulgaria

 GENTAUR BULGARIA
53 Iskar Str. 1191 Kokalyane, Sofia
Tel 0035924682280 
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR France

     GENTAUR France SARL
    9, rue Lagrange, 75005 Paris 
    Tel 01 43 25 01 50 
    Fax 01 43 25 01 60
    This email address is being protected from spambots. You need JavaScript enabled to view it.
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Germany

      GmbH Marienbongard 20
    52062 Aachen Deutschland
    Tel (+49) 0241 56 00 99 68 
    Fax (+49) 0241 56 00 47 88 
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    This email address is being protected from spambots. You need JavaScript enabled to view it.

     

    Gentaur London

     GENTAUR Ltd. 
    Howard Frank Turnberry House 
    1404-1410 High Road 
    Whetstone London N20 9BH 
    Tel 020 3393 8531 
    Fax 020 8445 9411
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Poland

     GENTAUR Poland Sp. z o.o. 

    ul. Grunwaldzka 88/A m.2

    81-771 Sopot, Poland
    Tel  058 710 33 44
    Fax 058 710 33 48 
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Nederland

     GENTAUR Nederland BV
    Kuiper 1 
    5521 DG Eersel Nederland
    Tel 0208-080893 
    Fax 0497-517897
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Italy

     GENTAUR SRL IVA IT03841300167

    Piazza Giacomo Matteotti, 6, 24122 Bergamo
    Tel 02 36 00 65 93 
    Fax 02 36 00 65 94
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Spain

     GENTAUR Spain
    Tel 0911876558
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Genprice USA
    Gentaur Serbia

    serbiaSerbia, Macedonia FlagMacedonia, 

    montenegro-flagMontenegro, croatiaCroatia: 
    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Romania

    romGENTAUR Romania

    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Greece

    grGENTAUR Greece 

    Tel 00302111768494 
    Fax 0032 16 50 90 45

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Other countries

    Other countries
    Luxembourg +35220880274
    Schweiz Züri +41435006251
    Danmark +4569918806
    Österreich +43720880899
    Ceská republika Praha +420246019719
    Ireland Dublin +35316526556
    Norge Oslo +4721031366
    Finland Helsset +358942419041
    Sverige Stockholm +46852503438
    Magyarország Budapest +3619980547

    seal-in-search-symantec

     

     

    Articles

    Platelet Immunology: MAIPA

    immunologyMonoclonal Antibody-specific Immobilization of Platelet Antigen (MAIPA) is a qualitative technique for platelet antibody detection and/or identification and is considered to be the gold standard method in the platelet immunology field.

    We offer all cells, control plasma, reagents and materials necessary to perform the MAIPA procedure. The products are either offered as a complete MAIPA kit or as separate modules allowing to order reagents for defined steps of the MAIPA procedure:

    • Platelet-Antibody Screening Cells, Ref. 900001
    • Platelet-Antibody Identification Panel Cells Kit, Ref. 900002
    • Control Plasma Kit, Ref. 900003
    • MAIPA Reagents Kit, Ref. 900004
    • MAIPA ELISA Detection Kit, Ref. 900005
    • Complete MAIPA Kit, Ref. 900006

    The ready-to-use human Platelet-Antibody Screening Cells & Platelet-Antibody Identification Panel Cells are manufactured by employing a special proprietary production process. The standardized antibody screening panel allows the sensitive detection of anti-HPA antibodies, while the platelet antibody identification panel offers the ability to reliably identify the antibodies. These thrombocyte reagents are especially recommended for the MAIPA procedure and are advantageous for standardization, handling and workflow organization in the platelet immunology laboratory. The human thrombocytes are typed for HPA-1, -2, -3, -4, -5, -6 and -15. The use of well-characterized thrombocytes offers the ability to standardize the MAIPA: the thrombocyte reagents allow the use of typed cells expressing even rare antigen combinations such as HPA-1(a-,b+)[2,5%] or HPA-5(a-,b+)[less than 1%] for an extended period of time. The stability if the platelet preparations and platelet antigens is guaranteed until indicated expiry date if stored at 2-8°C. 

     Detection and identification of allo- or auto-antibodies against platelets is indispensable for a targeted therapy of three clinical symptoms in platelet transfusions:

    • Neonatal/Fetal Allo-Immune Thrombocytopenia (NAIT)
    • Post-Transfusion Purpura (PTP)
    • Platelet Refractoriness (PR)

    NAIT: Feto-maternal incompatibility of human platelet allo-antigens may induce antibodies to Human Platelet Antigens (anti-HPA) which may lead to a neonatal/fetal allo-immune thrombocytopenia (NAIT/FNAIT). The mother produces antibodies against fetus' antigens inherited from the father. These allo-antibodies (IgG) can cross the placenta, destroy fetal thrombocytes and may induce severe thrombocytopenia. It is most commenly caused by the HPA-1a antigen (80%). NAIT has an estimated incidence of 1/1000 pregnancies and may lead to intra-cerebral bleeding and/or ventriculomegaly. Typing the maternal platelets for the HPA-1a antigen should be performed systematically. Screening and identification of maternal antibodies has to be done for prevention and treatment of such manifestations.

    PTP: Post-Transfusion Purpura is an adverse reaction to a blood transfusion due to donor platelet antigens being different from patient platelet antigens. Allo-antibodies destroy the transfused platelets and auto-antibodies destroy the patient's own platelets, leading to a severe form of thrombocytopenia that lasts for several weeks and sometimes even months. It is most commonly caused by the HPA-1a antigen. PTP is most common in HPA-1a negative women who have had multiple pregnancies, while in men PTP may occur after having undergone previous tranfusions. This adverse reaction to blood transfusion typically occurs 10 days following a transfusion. The thrombocytopenia can be treated with therapeutic intravenous immunoglobulin (IVIgG). Other platelet allo-antigens are occasionally implicated in post transfusion purpura.

    PR: Long-term application of platelet concentrates may induce anti-HLA and anti-HPA antibodies. These patient antibodies destroy transfused platelets and prevent successful therapy. The use of matched platelets saves valuable resources and costs whilst minimizing concomitant risks of platelet concentrate transfusion such as bacterial or cytokine load. Characterization of the allo-antibodies is an important step in improving the efficacy of platelet transfusion. Of the platelet antigens involved in platelet refractoriness upon platelet transfusion the most prominent allo-immunization is caused by the HPA-5b platelet antigen followed by the HPA-1a allo-antigen. Typing donors and recipients for HPA-1a and HPA-5b antigens is of utmost importance, screening and identification of antibodies has to be done to achieve an effective platelet transfusion treatment.